$CDXC News Article - A Milestone Phase I Randomize
Post# of 46
(Total Views: 71)
Posted On: 11/30/2023 12:05:48 PM
$CDXC News Article - A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen , Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD) https://marketwirenews.com/news-releases/a-mi...91881.html
(0)
(0)Chromadex Corp (CDXC) Stock Research Links
My Twitter: WhyteStocks
Scroll down for more posts ▼